Specialized cholangiocarcinoma care including intrahepatic and extrahepatic bile duct cancer with advanced chemotherapy, targeted therapy, and comprehensive multidisciplinary management.
Expert management of cholangiocarcinoma including intrahepatic, perihilar, and distal bile duct cancer. We specialize in gemcitabine-based regimens, targeted therapies, and comprehensive palliative care.
MRCP, CT cholangiography, and endoscopic retrograde cholangiopancreatography (ERCP) for accurate staging.
CA19-9, CEA, and molecular profiling including FGFR2 fusions and IDH1/2 mutations.
Core needle biopsy, brush cytology, and immunohistochemistry for accurate diagnosis.
Yellowing of skin/eyes, dark urine, pale stools, and itching due to bile duct obstruction.
Right upper quadrant pain, abdominal fullness, nausea, or poor appetite.
Unintended weight loss, fatigue, low-grade fever in some cases.
Primary sclerosing cholangitis, biliary duct cysts, recurrent biliary infections.
Hepatitis B/C, cirrhosis, NAFLD/NASH increase risk of cholangiocarcinoma.
Exposure to certain toxins, family history, and genetic predisposition.
Regular CA19-9 monitoring, imaging studies, and biliary function assessment for treatment optimization.
Collaboration with hepatobiliary surgery, interventional radiology, and gastroenterology specialists.
Managing biliary obstruction, pruritus, and maintaining quality of life throughout treatment.